Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with liver fluke: drug trial launches

NCT ID NCT07262814

Disease control Sponsor: Jennifer Keiser Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 5 times

Summary

This study tests different doses of a drug called arpraziquantel in children aged 6-7 who are infected with a liver fluke parasite (Opisthorchis viverrini). The goal is to find the safest and most effective dose to cure the infection. 125 children will receive one of several doses, and researchers will check if the parasite is gone after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
arpraziquantel (a drug to treat parasitic worm infections)
What this could lead to
If successful, this could provide a safe and effective treatment for liver fluke infection in young children, helping to reduce disease burden in affected communities.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 125 children. The optimal dose may not be found, or the drug may not work as well as hoped. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 7 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 6 to 7 years (i.e., 72 to 95 months). * Written informed consent signed by parents/caregivers (signature or thumbprint). * Agree to comply with study procedures, including provision of two stool samples at baseline and at follow-up assessment 21-28 days after treatment, respectively. * Willing to be examined by a study physician prior to treatment. * At least two slides of the quadruple Kato-Katz thick smears positive for O. viverrini. Exclusion Criteria: * Presence or signs of major systemic illness, e.g. severe anaemia (haemoglobin level of \< 80 g/L according to WHO) upon initial clinical assessment. * Known or suspected infection with Taenia solium (cysticercosis). * Known or suspected acute schistosomiasis. * Abnormal liver and kidney function. * Use of anthelminthic drugs within 4 weeks before or during study period. * Known allergy to study medications (i.e. praziquantel or any of the excipients). * Being prescribed or taking concomitantly medication with known contraindication or drug interactions with the study medication. * Concurrent participation in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opisthorchis viverrini are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opisthorchiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opisthorchis viverrini

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lao Tropical and Public Health Institute (Lao TPHI)

    RECRUITING

    Vientiane, Laos

More trials for these conditions

Other studies related to the condition(s) this trial covers.